On the morning of August 27, 1942 C.E., a Polish immigrant known only as JD received an injection at Yale–New Haven Hospital. He had non-Hodgkin’s lymphoma and had run out of options. What happened next — a dramatic, if temporary, shrinkage of his tumors — would quietly launch one of medicine’s most consequential chapters.
What the evidence shows
- Cancer chemotherapy: Two Yale pharmacologists, Louis S. Goodman and Alfred Gilman, were recruited by the U.S. Department of Defense to study chemical warfare agents — and discovered one had potential against lymphoma.
- Nitrogen mustard: Goodman and Gilman stabilized a derivative of mustard gas by replacing a sulfur atom with nitrogen, producing mustine — the first anticancer chemotherapeutic agent injected into a human patient.
- Patient JD: The first recipient of mustine treatment showed measurable tumor reduction after his injections in 1942 C.E., though the effect lasted only weeks; he died on December 1, 1942 C.E., 96 days after his first dose.
From battlefield poison to hospital ward
The road to chemotherapy ran through the trenches of World War I. Mustard gas, deployed by German forces, was one of the most feared chemical weapons of that conflict. Though banned by the Geneva Protocol in 1925 C.E., the approach of World War II reignited fears about chemical warfare — and prompted the U.S. military to investigate whether these deadly compounds might have any therapeutic value.
Goodman and Gilman took up that question at Yale School of Medicine. Working under a classified U.S. Department of Defense contract, they noticed that mustard gas decimated rapidly dividing cells — precisely the kind of cells that define aggressive cancers like lymphoma. Mustard gas itself was too volatile to use clinically, but by swapping a sulfur atom for nitrogen, they produced a more stable compound: mustine.
Animal experiments came first. The researchers established lymphomas in mice and showed the compound could shrink them. With thoracic surgeon Gustaf Lindskog joining the effort, they moved to human application — and JD became their patient.
What happened to patient JD
JD’s tumor masses shrank measurably after treatment. For the physicians watching, it was a revelation: a pharmacological agent had visibly acted on a cancer. That had never been documented before in a controlled clinical setting.
But the remission was short-lived. JD required further treatment, and the disease eventually won. He died 96 days after his first injection. The results were kept secret during wartime and not published until 1946 C.E., when they appeared in The New York Times.
The story of JD — his full name never recorded in the published literature — sits at a complicated intersection of medicine, military secrecy, and research ethics. He gave his life, in a sense, so that a principle could be proved: cancer was not necessarily beyond the reach of drugs.
A second path opens: antifolates and folic acid
Even as the nitrogen mustard work remained classified, another line of inquiry was forming. Sidney Farber at Harvard Medical School began studying folic acid in children with leukemia. Folic acid — a vitamin essential to DNA metabolism — had been identified by Lucy Wills while working in India in 1937 C.E. Farber’s collaborators, including Harriett Kiltie and Yellapragada SubbaRow of Lederle Laboratories, synthesized folate analogues that blocked the enzyme pathways cancer cells needed to proliferate.
When Farber administered aminopterin to children with acute lymphoblastic leukemia in 1948 C.E., he saw remissions. They were brief — but they were real. The medical establishment met his findings with ridicule. His 1948 C.E. report in the New England Journal of Medicine was widely dismissed. History proved him correct.
These two streams — nitrogen mustards from Goodman and Gilman, antifolates from Farber and his collaborators — became the twin foundations of modern cancer chemotherapy.
Lasting impact
The 1942 C.E. trial established that cancer could be treated pharmacologically — a premise that now seems obvious but was genuinely radical at the time. From that single injection grew an entire scientific discipline. The Cancer Chemotherapy National Service Center, created by the U.S. National Cancer Institute in 1955 C.E., institutionalized drug discovery for cancer for the first time, developing the cell lines and animal models that researchers worldwide still use.
By 1965 C.E., combination chemotherapy — using multiple drugs simultaneously to prevent resistance — was producing long-term remissions in children with leukemia. Researchers Jane C. Wright, Roy Hertz, and Min Chiu Li demonstrated that methotrexate alone could cure choriocarcinoma, making it the first solid cancer cured by chemotherapy. The vinca alkaloids, derived from the Madagascar periwinkle, added another class of agents. Each advance traced a direct line back to that 1942 C.E. experiment.
Today, chemotherapy forms part of a broader toolkit that includes immunotherapy, targeted therapies, and precision oncology. The World Health Organization estimates that cancer survival rates have improved substantially in high-income countries over recent decades — largely because of treatments that began with Goodman, Gilman, and a patient whose name we still do not know.
Blindspots and limits
The early chemotherapy trials operated under wartime secrecy and with informed consent standards far below what medicine now requires — JD’s identity was never preserved in published records, and his autonomy in the process remains unclear. The benefits of chemotherapy also spread unevenly: access to cancer treatment today remains deeply unequal across income levels and geographies, and many of the side effects that marked early nitrogen mustard treatments — severe toxicity, immunosuppression — continue to burden patients globally. Chemotherapy has saved millions of lives, but it has never been a clean or easy victory.
Read more
For more on this story, see: History of cancer chemotherapy — Wikipedia
For more from Good News for Humankind, see:
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- U.K. cancer death rates down to their lowest level on record
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
More Good News
-
UK cancer death rates reach their lowest level ever recorded
Cancer death rates in the United Kingdom have fallen to the lowest level ever recorded, according to Cancer Research UK data published in 2026. Age-standardized mortality rates have dropped by more than 25% over the past two decades, driven by advances in lung, bowel, and breast cancer treatment and diagnosis. Expanded NHS screening programs, immunotherapy, and targeted drug therapies are credited as key factors behind the sustained decline. The achievement represents generations of compounding progress across research, clinical care, and public health, though significant inequalities in cancer survival persist across socioeconomic and geographic lines.
-
California condors nest on Yurok land in the Pacific Northwest for the first time in over a century
California condors are nesting in the Pacific Northwest for the first time in over a century, on Yurok Tribe territory in Northern California. The confirmed nest marks a landmark moment in condor recovery and represents deep cultural restoration for the Yurok people, who consider the condor — prey-go-neesh — a sacred relative. The Yurok Tribe has led reintroduction efforts since 2008, combining Indigenous ecological knowledge with conventional conservation science. Successful wild nesting signals the recovering population is crossing a critical threshold, demonstrating that Indigenous-led conservation produces measurable, meaningful results.
-
Canada commits .8 billion to protect 30% of its lands and waters by 2030
Canada 30×30 conservation commitment: Canada has pledged .8 billion to protect 30% of its lands and waters by 2030, one of the largest conservation investments in the country’s history. Prime Minister Mark Carney announced the plan under the global Kunming-Montréal biodiversity framework, with Indigenous-led conservation and Guardians programs at its center. The commitment matters globally because Canada’s boreal forests, Arctic tundra, and freshwater systems regulate climate far beyond its borders. Whether the pledge delivers lasting protection will depend on the strength of legal frameworks and the quality of Indigenous partnership.
